Furthermore, in nasopharyngeal carcinoma, the combination of gemcitabine with APG‐1252, a novel inhibitor of Bcl‐2/Bcl‐xl, exhibited additive antitumor effects. Here, BCL2L1 is linked to nasopharyngeal carcinoma.